Navigating the Volatility of NeuroSense Therapeutics Ltd’s (NRSN) Stock

In the past week, NRSN stock has gone up by 20.59%, with a monthly decline of -2.84% and a quarterly surge of 156.25%. The volatility ratio for the week is 8.56%, and the volatility levels for the last 30 days are 11.67% for NeuroSense Therapeutics Ltd The simple moving average for the past 20 days is 19.10% for NRSN’s stock, with a 94.12% simple moving average for the past 200 days.

Is It Worth Investing in NeuroSense Therapeutics Ltd (NASDAQ: NRSN) Right Now?

NRSN has 36-month beta value of 1.57. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for NRSN is 9.14M, and currently, short sellers hold a 0.38% ratio of that float. The average trading volume of NRSN on April 04, 2024 was 294.01K shares.

NRSN) stock’s latest price update

The stock of NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has increased by 11.41 when compared to last closing price of 1.84.Despite this, the company has seen a gain of 20.59% in its stock price over the last five trading days. PRNewsWire reported 2023-11-09 that – Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial – Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass., Nov. 9, 2023 /PRNewswire/ — NeuroSense Therapeutics Ltd.

NRSN Trading at 37.48% from the 50-Day Moving Average

After a stumble in the market that brought NRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.02% of loss for the given period.

Volatility was left at 11.67%, however, over the last 30 days, the volatility rate increased by 8.56%, as shares surge +0.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +113.99% upper at present.

During the last 5 trading sessions, NRSN rose by +20.59%, which changed the moving average for the period of 200-days by +11.41% in comparison to the 20-day moving average, which settled at $1.7200. In addition, NeuroSense Therapeutics Ltd saw 161.15% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for NRSN

The total capital return value is set at -5.2. Equity return is now at value -300.13, with -157.09 for asset returns.

Based on NeuroSense Therapeutics Ltd (NRSN), the company’s capital structure generated -0.75 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at -0.43. The interest coverage ratio of the stock is -6.22.

Currently, EBITDA for the company is -13.38 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.82.

Conclusion

To put it simply, NeuroSense Therapeutics Ltd (NRSN) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts